

Registration number: 05116536

**PREPARED FOR THE REGISTRAR  
NEURAL PATHWAYS (UK) LIMITED  
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS  
FOR THE PERIOD FROM 1 APRIL 2021 TO 30 SEPTEMBER 2022**

Hazlewoods LLP  
Windsor House  
Bayshill Road  
Cheltenham  
GL50 3AT

FRIDAY



\*AC6T5ØJV\*

A40

30/06/2023

#82

COMPANIES HOUSE

**NEURAL PATHWAYS (UK) LIMITED**

**CONTENTS**

Company Information	1
Balance Sheet	2
Notes to the Unaudited Financial Statements	3 to 5

## **NEURAL PATHWAYS (UK) LIMITED**

### **COMPANY INFORMATION**

<b>Directors</b>	W M Irving K Lineker
<b>Registered office</b>	1 Suffolk Way Sevenoaks Kent TN13 1YL
<b>Accountants</b>	Hazlewoods LLP <i>Windsor House</i> Bayshill Road Cheltenham GL50 3AT

**NEURAL PATHWAYS (UK) LIMITED**

**(REGISTRATION NUMBER: 05116536)  
BALANCE SHEET AS AT 30 SEPTEMBER 2022**

	Note	30 September 2022 £	31 March 2021 £
<b>Current assets</b>			
Debtors: Amounts falling due after more than one year	4	<u>754,940</u>	<u>676,755</u>
<b>Capital and reserves</b>			
Called up share capital	5	2	2
Profit and loss account		<u>754,938</u>	<u>676,753</u>
Total equity		<u>754,940</u>	<u>676,755</u>

For the financial period ending 30 September 2022 the company was entitled to exemption from audit under section 479A of the Companies Act 2006 relating to subsidiary companies.

**Directors' responsibilities:**

- The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

29/6/2023

Approved and authorised by the Board on ..... and signed on its behalf by:



.....  
K Lineker  
Director

The notes on pages 3 to 5 form an integral part of these financial statements.

## **NEURAL PATHWAYS (UK) LIMITED**

### **NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2021 TO 30 SEPTEMBER 2022**

#### **1 General information**

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:

1 Suffolk Way  
Sevenoaks  
Kent  
TN13 1YL

#### **2 Accounting policies**

##### **Summary of significant accounting policies and key accounting estimates**

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

##### **Statement of compliance**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

##### **Basis of preparation**

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

##### **Name of parent of group**

These financial statements are consolidated in the financial statements of Ruby Holdco Ltd.

The financial statements of Ruby Holdco Limited may be obtained from Companies House.

##### **Disclosure of long or short period**

The financial statements cover a period of 548 days. The accounting period has been lengthened to bring the year end in line with that of its ultimate parent undertaking, Ruby Holdco Limited.

##### **Going concern**

Following the period end, the directors of the group headed by Ruby Holdco Limited have commenced a simplification of the group structure which involves the liquidation of certain group entities. As a result of this decision, Huntercombe Group Holdco Limited will cease to trade and therefore the directors have prepared the accounts on a basis other than the going concern basis.

As a result of preparing the accounts on this basis, the company's assets have been written down to their net realisable value and all assets and liabilities have been presented as current. No provision has been included in respect of the costs of terminating the business unless such costs were committed at the balance sheet date.

##### **Judgements and estimation uncertainty**

These financial statements do not contain any significant judgements or estimation uncertainty.

##### **Share capital**

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

## NEURAL PATHWAYS (UK) LIMITED

### NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2021 TO 30 SEPTEMBER 2022

#### Financial instruments

##### **Classification**

Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.

##### **Recognition and measurement**

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

##### **Impairment**

Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the financial asset's original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset's carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

**NEURAL PATHWAYS (UK) LIMITED****NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE PERIOD FROM 1 APRIL 2021 TO 30 SEPTEMBER 2022****3 Staff numbers**

All staff costs and directors remuneration have been borne by another group undertaking. There were no employees in the company other than the directors.

	<b>1 April 2021 to 30 September 2022 No.</b>	<b>Year ended 31 March 2021 No.</b>
Average number of employees	<u>3</u>	<u>2</u>

**4 Debtors**

	<b>30 September 2022 £</b>	<b>31 March 2021 £</b>
Amounts owed by group undertakings	754,940	676,755
Less non-current portion	<u>(754,940)</u>	<u>(676,755)</u>
Total current trade and other debtors	<u>-</u>	<u>-</u>

**Details of non-current trade and other debtors**

£754,940 (2021 - £676,755) of amounts owed to group undertakings is classified as non-current.

**5 Share capital****Allotted, called up and fully paid shares**

	<b>30 September 2022 No.</b>	<b>£</b>	<b>31 March 2021 No.</b>	<b>£</b>
Ordinary shares of £1 each	<u>2</u>	<u>2</u>	<u>2</u>	<u>2</u>

**6 Contingent liabilities**

The company is bound by an intra-group cross guarantee in respect of bank debt with other members of the group headed by its ultimate parent undertaking, Ruby Holdco Limited. The amount guaranteed is £165,524,000 (2021 - £140,000,000).

**7 Parent and ultimate parent undertaking**

The company's immediate parent undertaking is Active Assistance Finance Limited, incorporated in England and Wales.

The ultimate parent undertaking is Ruby Holdco Limited, incorporated in England and Wales.

The most senior parent entity producing publicly available financial statements is Ruby Holdco Limited. These financial statements are available upon request from Companies House.

The ultimate controlling party is Montreux Healthcare Fund.

**8 Disclosure under Section 444(5B) CA 2006**

As permitted by Section 444 CA 2006, these accounts do not contain a copy of the company's Profit and Loss account or a copy of the Directors' Report. These accounts are unaudited.